FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:476-487 February 3, 2005 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Colorectal cancer is the third most common malignant disease and the second most frequent cause of cancer-related death in the United States, with 145,290 new cases and 56,290 deaths anticipated in 2005.¹ Worldwide, colorectal cancer is the fourth most commonly diagnosed malignant disease, with an estimated 1,023,000 new cases and 529,000 deaths each year.²

When the role of systemic treatment for colorectal cancer was last reviewed in the Journal, in 1994,³ fluorouracil was the only effective chemotherapeutic drug for this cancer; much exciting progress has occurred since then. Accordingly, in this review, we will consider newer cytotoxic chemotherapies and biologic . . . [Full Text of this Article]

Staging and Other Prognostic Indicators

Fluoropyrimidines

Mechanisms of Action and Dose Scheduling of Fluorouracil

Oral Fluoropyrimidines

Adjuvant Therapy with Fluorouracil

Regional Therapy with Fluoropyrimidines

Irinotecan

Mechanisms of Action and Toxic Effects

Treatment of Metastatic Disease with Irinotecan

Oxaliplatin

Mechanisms of Action and Toxic Effects

Treatment of Metastatic Disease with Oxaliplatin

Is There an Optimal First-Line Therapy for Metastatic Disease?

Incorporation of Oxaliplatin and Irinotecan into Adjuvant Therapy

Targeted Therapies

Cetuximab

Bevacizumab

Future Directions and Challenges

Source Information

From the Department of Medical Oncology, Dana–Farber Cancer Institute; the Department of Medicine, Brigham and Women's Hospital; and the Department of Medicine, Harvard Medical School — all in Boston.

Address reprint requests to Dr. Meyerhardt at the Dana–Farber Cancer Institute, 44 Binney St., Boston, MA 02115.

Related Letters:

Therapy for Colorectal Cancer
Kountouras J., Zavos C., Chatzopoulos D., Jankilevich G., Masland W. S., Etzioni S., Rosenfeld K., Meyerhardt J. A., Mayer R. J.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:1820-1822, Apr 28, 2005. Correspondence

This article has been cited by other articles:

• Wolpin, B. M., Wei, E. K., Ng, K., Meyerhardt, J. A., Chan, J. A., Selhub, J., Giovannucci, E. L., Fuchs, C. S. (2008). Prediagnostic Plasma Folate and the Risk of Death in Patients With Colorectal Cancer. JCO 26: 3222-3228 [Abstract] [Full Text]  
• Walther, A, Houlston, R, Tomlinson, I (2008). Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 57: 941-950 [Abstract] [Full Text]  
• Sasaki, T., Nakamura, T., Rebhun, R. B., Cheng, H., Hale, K. S., Tsan, R. Z., Fidler, I. J., Langley, R. R. (2008). Modification of the Primary Tumor Microenvironment by Transforming Growth Factor {alpha}-Epidermal Growth Factor Receptor Signaling Promotes Metastasis in an Orthotopic Colon Cancer Model. Am. J. Pathol. 173: 205-216 [Abstract] [Full Text]  
• Correale, P., Tagliaferri, P., Fioravanti, A., Del Vecchio, M. T., Remondo, C., Montagnani, F., Rotundo, M. S., Ginanneschi, C., Martellucci, I., Francini, E., Cusi, M. G., Tassone, P., Francini, G. (2008). Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial). Clin. Cancer Res. 14: 4192-4199 [Abstract] [Full Text]  
• Pfeiffer, P., Nielsen, D., Bjerregaard, J., Qvortrup, C., Yilmaz, M., Jensen, B. (2008). Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 19: 1141-1145 [Abstract] [Full Text]  
• Wu, M.-P., Young, M.-J., Tzeng, C.-C., Tzeng, C.-R., Huang, K.-F., Wu, L.-W., Chou, C.-Y. (2008). A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer. Carcinogenesis 29: 1115-1123 [Abstract] [Full Text]  
• Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., Kerb, R., Blievernicht, J., Fischer, J., Hofmann, U., Bokemeyer, C., Eichelbaum, M. (2008). Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group. JCO 26: 2131-2138 [Abstract] [Full Text]  
• Glimelius, B., Sorbye, H., Balteskard, L., Bystrom, P., Pfeiffer, P., Tveit, K., Heikkila, R., Keldsen, N., Albertsson, M., Starkhammar, H., Garmo, H., Berglund, A. (2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 19: 909-914 [Abstract] [Full Text]  
• Yamada, M., Ichikawa, Y., Yamagishi, S., Momiyama, N., Ota, M., Fujii, S., Tanaka, K., Togo, S., Ohki, S., Shimada, H. (2008). Amphiregulin Is a Promising Prognostic Marker for Liver Metastases of Colorectal Cancer. Clin. Cancer Res. 14: 2351-2356 [Abstract] [Full Text]  
• Dib, E., Maia, M., Longo-Maugeri, I. M., Martins, M. C., Mussalem, J. S., Squaiella, C. C., Penha, F. M., Magalhaes, O. Jr, Rodrigues, E. B., Farah, M. E. (2008). Subretinal Bevacizumab Detection after Intravitreous Injection in Rabbits. IOVS 49: 1097-1100 [Abstract] [Full Text]  
• Tuynman, J. B., Vermeulen, L., Boon, E. M., Kemper, K., Zwinderman, A. H., Peppelenbosch, M. P., Richel, D. J. (2008). Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon Cancer. Cancer Res. 68: 1213-1220 [Abstract] [Full Text]  
• Landrum, M. B., Meara, E. R., Chandra, A., Guadagnoli, E., Keating, N. L. (2008). Is Spending More Always Wasteful? The Appropriateness Of Care And Outcomes Among Colorectal Cancer Patients. Health Aff (Millwood) 27: 159-168 [Abstract] [Full Text]  
• Lau, W. Y., Lai, E. C. H. (2007). Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma A Strategy to Increase Resectability. Ann. Surg. Oncol. 14: 3301-3309 [Abstract] [Full Text]  
• Troiani, T., Serkova, N. J., Gustafson, D. L., Henthorn, T. K., Lockerbie, O., Merz, A., Long, M., Morrow, M., Ciardiello, F., Eckhardt, S. G. (2007). Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model. Clin. Cancer Res. 13: 6450-6458 [Abstract] [Full Text]  
• Shen, L., Catalano, P. J., Benson, A. B. III, O'Dwyer, P., Hamilton, S. R., Issa, J.-P. J. (2007). Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil Based Chemotherapy. Clin. Cancer Res. 13: 6093-6098 [Abstract] [Full Text]  
• Tomlinson, J. S., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kornprat, P., Gonen, M., Kemeny, N., Brennan, M. F., Blumgart, L. H., D'Angelica, M. (2007). Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure. JCO 25: 4575-4580 [Abstract] [Full Text]  
• Mayer, R. J. (2007). Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer?. JCO 25: 4165-4167 [Full Text]  
• Figueras, J, Burdio, F, Ramos, E, Torras, J, Llado, L, Lopez-Ben, S, Codina-Barreras, A, Mojal, S (2007). Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections. Ann Oncol 18: 1190-1195 [Abstract] [Full Text]  
• Meyerhardt, J., Stuart, K, Fuchs, C., Zhu, A., Earle, C., Bhargava, P, Blaszkowsky, L, Enzinger, P, Mayer, R., Battu, S, Lawrence, C, Ryan, D. (2007). Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer. Ann Oncol 18: 1185-1189 [Abstract] [Full Text]  
• Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., Mayer, R. J. (2007). Adjuvant Treatment of Colorectal Cancer. CA Cancer J Clin 57: 168-185 [Abstract] [Full Text]  
• Morgillo, F., Kim, W.-Y., Kim, E. S., Ciardiello, F., Hong, W. K., Lee, H.-Y. (2007). Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non small Cell Lung Cancer Cells to Treatment with Gefitinib. Clin. Cancer Res. 13: 2795-2803 [Abstract] [Full Text]  
• Saadeh, C. E, Lee, H S. (2007). Panitumumab: A Fully Human Monoclonal Antibody with Activity in Metastatic Colorectal Cancer. The Annals of Pharmacotherapy 41: 606-613 [Abstract] [Full Text]  
• Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., Bardelli, A. (2007). Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti-Epidermal Growth Factor Receptor Antibody Therapies. Cancer Res. 67: 2643-2648 [Abstract] [Full Text]  
• Akasu, T., Yamaguchi, T., Fujimoto, Y., Ishiguro, S., Yamamoto, S., Fujita, S., Moriya, Y. (2007). Abdominal Sacral Resection for Posterior Pelvic Recurrence of Rectal Carcinoma: Analyses of Prognostic Factors and Recurrence Patterns. Ann. Surg. Oncol. 14: 74-83 [Abstract] [Full Text]  
• Goldberg, R. M., Rothenberg, M. L., Van Cutsem, E., Benson, A. B. III, Blanke, C. D., Diasio, R. B., Grothey, A., Lenz, H.-J., Meropol, N. J., Ramanathan, R. K., Becerra, C. H. R., Wickham, R., Armstrong, D., Viele, C. (2007). The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. The Oncologist 12: 38-50 [Abstract] [Full Text]  
• Bartlett, D. L., Berlin, J., Lauwers, G. Y., Messersmith, W. A., Petrelli, N. J., Venook, A. P. (2006). Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement. Ann. Surg. Oncol. 13: 1284-1292 [Full Text]  
• Perumal, M., Pillai, R. G., Barthel, H., Leyton, J., Latigo, J. R., Forster, M., Mitchell, F., Jackman, A. L., Aboagye, E. O. (2006). Redistribution of Nucleoside Transporters to the Cell Membrane Provides a Novel Approach for Imaging Thymidylate Synthase Inhibition by Positron Emission Tomography.. Cancer Res. 66: 8558-8564 [Abstract] [Full Text]  
• Meyerhardt, J. A., Giovannucci, E. L., Holmes, M. D., Chan, A. T., Chan, J. A., Colditz, G. A., Fuchs, C. S. (2006). Physical Activity and Survival After Colorectal Cancer Diagnosis. JCO 24: 3527-3534 [Abstract] [Full Text]  
• Schulz, S., Hyslop, T., Haaf, J., Bonaccorso, C., Nielsen, K., Witek, M. E., Birbe, R., Palazzo, J., Weinberg, D., Waldman, S. A. (2006). A Validated Quantitative Assay to Detect Occult Micrometastases by Reverse Transcriptase-Polymerase Chain Reaction of Guanylyl Cyclase C in Patients with Colorectal Cancer. Clin. Cancer Res. 12: 4545-4552 [Abstract] [Full Text]  
• Yang, A. D., Fan, F., Camp, E. R., van Buren, G., Liu, W., Somcio, R., Gray, M. J., Cheng, H., Hoff, P. M., Ellis, L. M. (2006). Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines.. Clin. Cancer Res. 12: 4147-4153 [Abstract] [Full Text]  
• Merrouche, Y., Mugneret, F., Cahn, J.-Y. (2006). Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer. Ann Oncol 17: 1025-1026 [Full Text]  
• Meyerhardt, J. A., Zhu, A. X., Enzinger, P. C., Ryan, D. P., Clark, J. W., Kulke, M. H., Earle, C. C., Vincitore, M., Michelini, A., Sheehan, S., Fuchs, C. S. (2006). Phase II Study of Capecitabine, Oxaliplatin, and Erlotinib in Previously Treated Patients With Metastastic Colorectal Cancer. JCO 24: 1892-1897 [Abstract] [Full Text]  
• Leonetti, C., Scarsella, M., Zupi, G., Zoli, W., Amadori, D., Medri, L., Fabbri, F., Rosetti, M., Ulivi, P., Cecconetto, L., Bolla, M., Tesei, A. (2006). Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts.. Molecular Cancer Therapeutics 5: 919-926 [Abstract] [Full Text]  
• Lubbe, W. J., Zhou, Z. Y., Fu, W., Zuzga, D., Schulz, S., Fridman, R., Muschel, R. J., Waldman, S. A., Pitari, G. M. (2006). Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer.. Clin. Cancer Res. 12: 1876-1882 [Abstract] [Full Text]  
• Pitari, G. M., Baksh, R. I., Harris, D. M., Li, P., Kazerounian, S., Waldman, S. A. (2005). Interruption of Homologous Desensitization in Cyclic Guanosine 3',5'-Monophosphate Signaling Restores Colon Cancer Cytostasis by Bacterial Enterotoxins. Cancer Res. 65: 11129-11135 [Abstract] [Full Text]  
• Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A. Jr, Goodman, S. N., David, K. A., Juhl, H., Kinzler, K. W., Vogelstein, B. (2005). Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA 102: 16368-16373 [Abstract] [Full Text]  
• Adjei, A. A., Hidalgo, M. (2005). Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy. JCO 23: 5386-5403 [Abstract] [Full Text]  
• Kountouras, J., Zavos, C., Chatzopoulos, D., Jankilevich, G., Masland, W. S., Etzioni, S., Rosenfeld, K., Meyerhardt, J. A., Mayer, R. J. (2005). Therapy for Colorectal Cancer. NEJM 352: 1820-1822 [Full Text]